The CRC pipeline is highly active and evolving. 8% of oncology’s R&D efforts are focused on CRC, and there have been 4,827 investigatory clinical trials focusing on CRC across the globe. As of May 2018, the CRC pipeline featured more than 850 products across all stages of clinical development. EGFR and VEGF inhibitors remain a key focus, particularly in regards to biosimilar development.
This report will allow you to access invaluable data on the biosimilars market.